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Chapter 6
Hypoxia enhances migration and invasion 
in glioblastoma by promoting a mesenchymal shift 













Glioblastoma (GBM) is the most common brain tumor in adults and the mesenchymal GBM 
subtype was reported to be the most malignant, presenting severe hypoxia and necrosis. 
Here, we investigated the possible role of a hypoxic microenvironment for inducing a 
mesenchymal and invasive phenotype. The exposure of non-mesenchymal SNB75 and U87 
cells to hypoxia induced a strong change in cell morphology that was accompanied by 
enhanced invasive capacity and the acquisition of mesenchymal marker expression. Further 
analyses showed the induction of HIF-1α and HIF-2α by hypoxia and exposure to digoxin, a 
cardiac glycoside known to inhibit HIF-1/2 expression, was able to prevent hypoxia-induced 
mesenchymal transition. ShRNA-mediated knockdown of HIF-1α, and not HIF-2α, prevented 
this transition, as well as the knockdown of the EMT transcription factor ZEB1. We provide 
further evidence for a hypoxia-induced mesenchymal shift in GBM primary material by 
showing co-localization of GLUT1, ZEB1 and mesenchymal marker YKL40 in hypoxic regions 
of the tumor. Collectively, our results identify a HIF-1α–ZEB1 signaling axis that promotes 
hypoxia induced mesenchymal shift and invasion in GBM in a cell line dependent fashion.
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Introduction
Glioblastoma (GBM) is the most aggressive brain tumor, and despite multimodal treatment 
with surgery, radiation and chemotherapy patients generally show incurable relapse 
of the disease [1]. The median survival time of patients with GBM is less than 16 months 
even after optimal treatment [2]. Recent advancements in genomic sequencing and 
transcriptome analyses have stratified GBM into different molecular subtypes [3,4], of which 
the mesenchymal (MES) and proneural (PN) subtypes appear to be the most pronounced 
[5]. A mesenchymal phenotype in GBM has been associated with tumor aggressiveness 
and elevated invasive potential [4,6]. Interestingly, high levels of tumor necrosis were 
observed in tumors of patients having a mesenchymal subtype [4]. Furthermore, a recent 
study demonstrated that GBM cells surrounding necrotic zones and suffering from hypoxic 
conditions express high levels of the mesenchymal transcription factors C/EBP-β and C/
EBP-δ and, in addition, the expression of these transcription factors was associated with a 
poor prognosis [7].
 GBMs generally display rapid cell proliferation and inadequate vascularization leading 
frequently to tumor areas with insufficient oxygen supply [8]. This chronic exposure to 
extremely low levels of oxygen frequently produces necrotic zones surrounded by densely 
packed hypoxic tumor cells. These so-called pseudopalisading GBM cells were shown 
to express hypoxia-regulated genes that control crucial processes associated with tumor 
aggressiveness such as angiogenesis, extracellular matrix degradation, and invasive 
behavior [7,9]. Hypoxia is also a well-recognized component of the tumor microenvironment 
and has been linked to poor patient outcome and resistance to therapies in different cancer 
types [10-15].
 The cellular responses to hypoxia are generally mediated by the hypoxia-inducible factor 
(HIF) family of transcription factors [16,17]. HIFs function as heterodimers composed of an 
oxygen-sensitive HIF-α subunit and a constitutively expressed HIF-β subunit. Under normoxic 
conditions, HIF-α is subjected to proteasomal degradation as a result of ubiquitination by 
the von Hippel–Lindau (vHL) tumor-suppressor gene product. Under hypoxic conditions, 
however, the interaction between HIF-α and vHL is abrogated and as a consequence of 
this the HIF-α subunit is stabilized, thereby allowing dimerization with HIF-β and subsequent 
binding to hypoxia-responsive elements (HREs) in the promoters of hypoxia-regulated 
genes. In this way the transcription of hundreds of downstream genes are regulated that 
can modulate cell survival, motility, metabolism and angiogenesis in order to restore oxygen 
homeostasis [16,18,19]. Two HIF-α subunits, HIF-1α and HIF-2α, are structurally similar in 
their DNA binding and dimerization domains, but show differences in their transactivation 
domain. HIF-1α and HIF-2α are known to have non-overlapping biological roles each having 
unique target genes and requiring different levels of oxygen for activation [20].
 Hypoxia is a well-known inducer of the epithelial to mesenchymal transition (EMT) 
program in epithelial cancers like pancreatic ductal adenocarcinoma [21], hepatocellular 
carcinoma [22], ovarian carcinoma [23] and lung cancer [24]. EMT can contribute toward the 
Hypoxia-mediated MES transition in GBM | 127
invasion–metastasis cascade by inducing mesenchymal properties in tumor cells, including 
anoikis resistance and the ability to migrate and invade surrounding tissues [25]. Although 
the invasive phenotype of GBM is one of the major reasons for the poor prognosis associated 
with this disease, the involvement of hypoxia-induced mesenchymal transition has been 
hardly explored [26,27].
 In the present study we examined whether hypoxia can induce a mesenchymal shift in 
GBM cells and explored the consequences for their invasive behavior and the underlying 
molecular mechanisms involved. We provide evidence for the concept that GBM cells 
undergo a mesenchymal transition in necrotic areas of the tumor thus facilitating the invasive 
behavior of the tumor.
Materials and methods
Cell lines and treatments
The human GBM cell lines U87 and SNB75 were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) and U251 was obtained from the CLS Cell Lines 
Service GmbH (Eppelheim, Germany). U87 was cultured on cell culture flasks pre-coated with 
1% gelatine from porcine skin (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands) 
in Dulbecco’s modified Eagle’s Medium high glucose (DMEM-Hg) (Gibco Life Technologies, 
Bleiswijk, The Netherlands) medium supplemented with 10% FCS and 1% pen/strep (Gibco 
Life Technologies). SNB75 and U251 did not require gelatin coating of the flasks. Cell lines 
were maintained at 37 °C in a humidified atmosphere with 5% CO2. When indicated, cells 
were treated with the HIF-1α and HIF-2α inhibitor digoxin (Axon Medchem, Groningen, The 
Netherlands). The inhibitor was added at a concentration of 150 nM 2 hours prior to exposing 
the cells to hypoxia.
 For hypoxia treatment, cells were first maintained in the regular normoxic incubator for 
around 12 h until the cells attached to the flasks. Following this the flasks were transferred 
to the tri-gas incubator (Sanyo MCO 18M, from Sanyo E&E Europe BV, Etten-Leur, The 
Netherlands) filled with 1% O2, 5% CO2 and 94% N2, at 98% humidity and 37°C.
Western blotting
Preparation of protein lysates and Western blotting was carried out as described previously 
[28]. The membranes were probed with antibodies against HIF-1α (1:1000, abcam [ab2185], 
Cambridge, UK), HIF-2α (1:500, abcam [ab199]), SNAI1/SNAIL1 (1:500, Santa Cruz 
Biotechnology Inc [sc-10433], Santa Cruz, CA, USA), SLUG/SNAIL2 (1:500, Santa Cruz 
Biotechnology Inc [sc-166476]), ZEB1 (1:500, Santa Cruz Biotechnology Inc [sc-81428]), 
Twist (1:1000 abcam, [ab50581]), fibronectin (1:2500, BD Transduction Laboratories 
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[610077], Franklin Lakes, NJ, USA) and COL5A1 (1:2000, Santa Cruz Biotechnology, Inc 
[sc-20648]). β-Actin (1:10,000, MP Biomedicals [08691001], Duiven, The Netherlands) 
expression levels served as loading control. After incubation with primary antibodies 
membranes were washed with TBS-T (20 mmol/l Tris–HCL (pH 8.0), 137 mmol/l NaCl and 
0.1% Tween-20), and reprobed with appropriate HRP-conjugated secondary antibodies, anti-
mouse immunoglobulin G (IgG), anti-rabbit IgG or anti-goat IgG (Dako, Glostrup, Denmark) 
for 1 hour at room temperature. Proteins were visualized by chemiluminescence using BM 
chemiluminescence detection kit (Roche Applied Science, Almere, The Netherlands).
Immunofluorescence microscopy
Cells cultured on poly-L-lysine (Sigma-Aldrich)-coated cover slips were fixed for 10 minutes 
using 4% formaldehyde. After 3 times washing with cold PBS, cells were permeabilized 
with 0.1% Triton (Sigma-Aldrich) in PBS, washed again with PBS followed by a blocking 
step for 1 hour with PBS with 0.1% Tween-20 (Sigma-Aldrich), 2% BSA (PAA Laboratories 
GmbH, Colbe, Germany) and 1:50 dilution of normal goat serum (Dako). Subsequently, 
cells were incubated with the indicated primary antibodies at room temperature for 
1.5 hours. Primary antibodies used were: purified anti-fibronectin (1:100, BD Transduction 
Laboratories [610077]), anti-COL5A1 (1:200, Santa Cruz Biotechnology [sc-20648]), anti-
HIF-1α (1:1000, abcam [ab2185]), anti-HIF-2α (1:100, abcam [ab199]) and anti-ZEB1 
(1:50, Santa Cruz Biotechnology Inc [sc-10572]). After 4 times washing with PBS, slides 
were incubated for 1 hour with appropriate secondary antibodies: goat anti-mouse Alexa 
488 (1:200, Life Technologies), Donkey anti-goat Alexa 488 (1:200) or goat anti-rabbit IgG 
Antibody, Cy3 conjugate (1:400, Millipore [AP132 C]). Hoechst (Sigma H6024) staining was 
performed for 5 minutes followed by mounting of the coverslips with Kaisers glycerin (Merck, 
Darmstadt, Germany). Cells were examined by fluorescent microscopy (Leica DM6000, 
Leica Microsystems GmbH, Mannheim, Germany) and images were captured using a Leica 
DFC360 FX camera.
Transwell invasion assay
The invasion potential was determined on Gelatin-coated transwell inserts with 8 µm pore 
size (Becton Dickinson B.V., Breda, The Netherlands). For this, cells were trypsinized and 
resuspended in 0.1% FCS containing medium. 150 µl of a cell suspension containing 5×104 
cells was added to the transwell in triplicates per condition. 10% FCS or 0.1% FCS was 
added to the lower wells as chemoattractants. Cells that migrated/invaded and appeared 
on the bottom surface of the transwell insert membrane were fixed with 75% methanol/25% 
acetic acid for 20 minutes and stained with 0.25% Coomassie blue in 45% methanol/10% 
acetic acid followed by washing with demi water. The membranes were subsequently cut 
out and mounted on microscopic slides for quantification. Representative pictures of the 
membranes with cells were acquired at 5× magnification and the total number of cells on fifty 
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individual fields per membrane were counted; average numbers and standard deviations of 
invading cells for every condition were calculated.
Wound-healing assay
The migratory capacity of cells was determined by wound-healing assays. Briefly, 2×105cells 
were seeded on poly-L-Lysine (Sigma-Aldrich) coated 6-well plates in culture medium; upon 
confluency a scratch was made using a P10 pipette tip. The rate of wound closure was 
monitored at different time points under a microscope.
Short interfering RNA silencing
Validated Stealth RNAi (OriGene SR304746, Rockville, MD, USA) specific for ZEB1 
was transfected into U87 cells by using Lipofectamine RNAiMAX (Invitrogen, Leek, The 
Netherlands) according to the manufacturer’s protocol. Trilencer-27 universal scrambled 
negative control siRNA (OriGene SR30004) was used as negative control. For shRNA 
silencing, a lentiviral vector expressing a short hairpin against HIF-1α was made by 
cloning the hairpin sequence from pSuper-puro-HIF1a1470 (kindly gifted by Daniel Chung, 
Massachusetts General Hospital, Boston, Massachusetts) into the pLVUT vector [29]. A 
short hairpin sequence against HIF-2a was constructed by cloning the hairpin sequence 
from pRetro-Super-HIF2a (obtained from Addgene, Cambridge, MA, USA, number 22100) 
into the pLVUT vector. A control vector was generated by cloning a hairpin against firefly 
luciferase into the pLVUT vector. Viral particles were generated and lentiviral transductions 
were performed to generate stable knockdowns as previously described [29]. In summary, 
lentiviral particles were harvested in DMEM-Hg medium and stored at -80 °C until further use. 
Cultured U87 cells were transduced in 3 consecutive rounds within 8–12 h intervals between 
each round with lentiviral supernatant supplemented with polybrene (0.004 mg/ml).
Immunohistochemistry
Formalin fixed paraffin-embedded 3 µm thick consecutive tissue sections were mounted on 
microscope slides and dried overnight at 55 °C. Tissue sections were deparaffinized in xylol 
and rehydrated in graded series of ethanol, and stained with hematoxylin and eosin (H&E). 
Antigen retrieval was performed using microwave pretreatment in pH 6.0 citrate buffer. 
Sections were treated with 0.3% H2O2 for 30 minutes and blocked for 1 hour with 2% BSA to 
reduce non-specific primary antibody binding. Incubation with the following antibodies was 
performed overnight at 4 °C: anti-ZEB1 (1:150, Sigma-Aldrich), anti-GLUT1 (1:100, Abcam) 
and anti-YKL40 (1:200, Santa Cruz Biotechnology Inc).
 As negative controls, primary antibodies were omitted. After incubation with primary 
antibodies suitable secondary antibodies conjugated to peroxidase (Dako) and appropriate 
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tertiary antibodies conjugated to peroxidase (Dako) were used. Staining was visualized by 
3,3′-diaminobenzidine and sections were counterstained with hematoxylin and mounted. 
Images of relevant sections were acquired using a C9600 NanoZoomer (Hamamatsu 
Photonics KK, Hamamatsu City, Japan).
Statistical analysis
In vitro data of three independent experiments were represented as the mean ± standard 
error of the mean (SEM) in the form of graphs using the GraphPad Prism version 5.01 
(GraphPad for Science, San Diego, CA). Statistical significance was calculated by Student’s 
t-tests unless otherwise mentioned in the Figure legends. P-values <0.05 were assumed as 
statistically significant for all the tests.
Results
Hypoxia induces a phenotype shift and increases migration/invasion in GBM cells
The exposure of U87, SNB75 and U251 cells to hypoxia (1% O2) for 72 hours resulted in 
a marked difference in their morphology compared to normoxia (20% O2) cultured cells 
particularly in U87 and SNB75. Under hypoxic conditions the cells had a more elongated 
morphology and were more loosely clustered than normoxia cultured cells (Figure 1A). The 
migration/invasion potential of U87 cells was tested using gelatin-coated transwell inserts. 
Hypoxia exposed cells demonstrated almost double the amount of migratory/invasive cells 
in comparison to cells cultured under normoxic conditions (Figure 1B, C).
Hypoxia promotes mesenchymal transdifferentiation that is associated with accumulation of nuclear 
HIF-1α, HIF-2α and ZEB1
We next explored if the hypoxia-dependent change in morphology could be the result of 
mesenchymal transition in GBM cells. Therefore the expression of several mesenchymal 
markers was examined by immunofluorescence microscopy in U87, SNB75 and U251 cells 
under hypoxic and normoxic conditions. Previously we found U87 and U251 to represent 
predominantly the classical/proneural subtype [28], and SNB75 cells also appeared to be 
mostly non-mesenchymal lacking fibronectin and COL5A1 expression (Figure 2B). A strong 
induction of fibronectin and COL5A1 expression was seen under hypoxic conditions in U87 
and SNB75 (Figure 2A, B), whereas the basal expression levels of YKL40 and vimentin 
remained unaltered (data not shown). In contrast, in U251 cells no such inductions were 
observed (Figure 2C) and rather a reduction in migration potential under hypoxic conditions 
was observed in wound-healing assays (Supplemental Figure 1A, B).
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Figure 1. Hypoxia induces a phenotypic shift and enhances the invasive phenotype in GBM cells. Representative Phase 
contrast microscopic pictures (10× magnification) of U87 and SNB75 cells undergoing phenotypic shift characterized 
by a more elongated and stretched morphology under hypoxia in comparison to the cells in normoxia, while U251 cells 
appear less affected by hypoxia (A). A representative transwell assay showing Coomassie Blue-stained U87 cells on 
the insert membranes, demonstrating enhanced invasive capacity under hypoxic conditions in comparison to cells 
under normoxia (B). Media containing 0.1% FCS was used as the control and 10% FCS served as the chemo-attractant. 
The quantification of the data is depicted as the mean of three independent experiments measured in triplicate ± SEM 
(C); **: P < 0.01.
 To explore the underlying mechanism of the hypoxia-induced mesenchymal shift 
we employed U87 cells and performed western blot analyses to evaluate the expression 
levels of HIF-1α and HIF-2α along with EMT-inducing transcription factors such as Snail1, 
Snail2/Slug, ZEB1 and TWIST, and fibronectin and COL5A1. The expression of both HIF-
1α and HIF-2α was strongly induced together with the mesenchymal markers fibronectin 
and COL5A1, and out of the transcription factors tested we could detect only ZEB1 to be 
significantly upregulated under hypoxia (Figure 2D). Of note, we detected the 124 kDa form 
of ZEB1 and not the larger ~200 kDa form, which are both known to be specific for ZEB1 
[30]. Further, immunofluorescence analysis revealed nuclear localization of HIF-1α, HIF-2α 
and ZEB1 in U87 cells under hypoxic conditions, while under normoxia little or no nuclear 
expression of these transcription factors was detected (Figure 2E). Of note, U251 cells that 
did not demonstrate a hypoxia-induced gain in mesenchymal marker expression showed 
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nuclear translocation of HIF-α, but not of ZEB1 (Supplemental Figure 1C, D). Time-course 
experiments showed accumulation of HIF-1α, HIF-2α and ZEB1 after 6 and 12 hours hypoxia 
exposure and mesenchymal differentiation became evident after 48 hours exposure as 
indicated by the appearance of fibronectin expression (Supplemental Figure 2). Thus, these 
results suggested the involvement of HIF-1α, HIF-2α and ZEB1 in inducing a mesenchymal 
shift.
Figure 2. Hypoxia induces a mesenchymal shift in GBM. Immunofluorescence analysis for mesenchymal markers 
(fibronectin and COL5A1) in U87, SNB75 and U251 cells exposed to hypoxia in comparison to normoxic growth 
conditions (20× magnification, A-C). Western blots show the elevated expression levels of multiple markers associated 
with a mesenchymal phenotype in U87 cells when cultured under hypoxic conditions (D). Immunofluorescence analysis 
revealed nuclear localization of HIF-1α, HIF-2α and ZEB1 in U87 cells exposed to hypoxia (40× magnification, E).
Digoxin effectively inhibits the hypoxia-induced mesenchymal shift and increase in invasion
To investigate further the role of HIFs in the hypoxia-induced mesenchymal shift, we employed 
a cardiac glycoside, digoxin, a well-known inhibitor of HIF-1α and HIF-2α. Digoxin is known to 
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have modest effects on global protein synthesis but is a very potent inhibitor of HIF-1α mRNA 
translation [31]. Different concentrations of digoxin were tested in hypoxia-exposed U87 
cells to examine which dose was effective in blocking the phenotypic shift. A concentration 
of 150 nM appeared effective and was also able to inhibit the accumulation of HIF-1α and 
fibronectin at the protein level (Supplemental Figure 3A, B). Higher concentrations of digoxin 
appeared toxic to the cells. 
Figure 3. Digoxin prevents the hypoxia-mediated induction of the mesenchymal shift and associated invasion. 
Representative phase contrast microscopic pictures (10× magnification) show the effect of hypoxia on the morphology 
of U87 cells in the presence and absence of digoxin (A). Western blots show the effect of digoxin on the expression of 
the indicated proteins in hypoxia exposed U87 cells (B). A representative transwell assay showing Coomassie Blue-
stained U87 cells on the membrane inserts (C). The quantification of the transwell assay is depicted in (D). The bars 
represent the mean of 3 independent experiments (each measured in triplicate) ± SEM; **: P< 0.01.
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 Digoxin added 2 hours prior to placing the cells under hypoxia effectively prevented 
the phenotypic shift and western blot analysis further revealed that digoxin also prevented 
largely the induction of HIF-1α and HIF-2α together with that of ZEB1, fibronectin and COL5A1 
(Figure 3A, B). Next we examined the effect of digoxin on the hypoxia-dependent increase 
of migration/invasion in U87 cells; a significant reduction (~2 fold) in the invasive potential 
of these cells was seen (Figure 3C, D), indicating essential roles of HIF-1α and/or HIF-2α in 
mesenchymal differentiation and enhanced invasive potential.
HIF-1α is instrumental for the induction of ZEB1, a mesenchymal shift and increased migration/invasion 
under hypoxia
We proceeded by examining which of the two HIFs are instrumental for inducing a 
mesenchymal shift. U87 cells were generated in which either HIF-1α or HIF-2α expression was 
stably silenced using selective shRNAs and control scrambled shRNA encoded by lentiviral 
vectors. Effective knockdown was confirmed at the protein level by western blotting and we 
found that the silencing of HIF-1α and not HIF-2α effectively prevented the induction of ZEB1 
and fibronectin expression under hypoxia (Figure 4A). In line with this, control and HIF-2α 
knockdown cells showed the characteristic shift in morphology upon hypoxia, whereas HIF-
1α knockdown cells appeared similar to normoxia cultured U87 cells (Figure 4B). The HIF-1α 
knockdown cells also showed a clear decline in the invasive potential in comparison to the 
HIF-2α knockdown and control cells under hypoxic conditions (Figure 4C, D).
ZEB1 mediates the hypoxia-induced mesenchymal shift and invasive phenotype
To further examine the role of ZEB1 we silenced the expression of ZEB1 with 2 different 
specific siRNAs in comparison to scrambled siRNAs. Exposure of siZEB1-I and siZEB1-
II-transfected U87 cells to hypoxia prevented the phenotypic shift while the control cells 
(mock and scrambled siRNA-treated) showed a visible morphological shift under hypoxia 
(Figure 5A). Western blotting confirmed inhibition of ZEB1 induction by hypoxia in the specific 
ZEB1 siRNA-transfected U87 cells together with an absence of fibronectin and COL5A1 
accumulation (Figure 5B). In ZEB1 knockdown cells HIF-1α induction remained as strong as 
in control cells indicating that HIF-1α acts upstream of ZEB1 in triggering a mesenchymal shift 
under hypoxia (Figure 5B). Significant reduction in the invasive potential was also observed 
in U87 cells under hypoxia following the silencing of ZEB1 (Figure 5C, D). This indicates that 
ZEB1 is a crucial mediator of the hypoxia-induced HIF-1α dependent mesenchymal shift and 
the invasive phenotype of these GBM cells.
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Figure 4. HIF-1α knockdown prevents hypoxia-induced mesenchymal transition. Western blot analyses show effective 
downregulation of HIF-1α and HIF-2α in U87 cells following shRNA-mediated gene silencing and exposure to hypoxia 
(A). The effects on ZEB1 and fibronectin expression levels were also examined. Representative phase contrast 
microscopic pictures (10× magnification) illustrated that U87 cells transfected with shHIF-2α or shSCR underwent a 
phenotypic shift under hypoxia, whereas U87-shHIF-1α cells largely retained their original morphology under hypoxic 
conditions (B). Representative pictures are displayed of a transwell assay showing Coomassie Blue-stained U87 
(shSCR, shHIF-1α, shHIF-2α) cells on the membrane inserts (C). A decreased invasive potential of HIF-1α knockdown 
cells under hypoxia was seen. 0.1% FCS containing media was used as the control and 10% FCS served as the chemo-
attractant. Quantified data for the number of invading cells per field are shown in (D) as mean ± SEM of 3 independent 
experiments; **: P<0.01, ***: P<0.001.
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Figure 5. ZEB1 silencing effectively prevents the hypoxia-induced mesenchymal shift and invasion. siRNA-mediated 
silencing of ZEB1 effectively prevented the hypoxia-induced phenotypic shift in U87 cells in comparison to the Mock 
and si-negative control treated cells (A). Representative phase contrast microscopic pictures (10× magnification) are 
shown. Western blot analysis showed the downregulation of ZEB1 following ZEB1-targeted siRNA administration, and 
the levels of HIF-1α, fibronectin and COL5A1 are also shown (B). A representative transwell assay showing Coomassie 
Blue-stained U87 cells on the membrane inserts, demonstrates decreased invasive potential under hypoxia following 
silencing of ZEB1 expression in comparison to the mock and negative siRNA-treated cells (C). The quantification of the 
number of invading cells per field is shown in (D), where bars indicate the average invading cells/field of 3 independent 
experiments ± SEM; ***: P<0.001.
Overlapping GLUT1, ZEB1 and YKL40 expression in patient material
Finally, in order to examine whether hypoxia-induced mesenchymal transition may 
also be relevant in patient tumors, we selected GBM patient material showing multiple 
pseudopalisading necrotic regions as was determined by H&E staining (Figure 6A). 
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Figure 6. Local/regional mesenchymal transition detected in hypoxic zones in GBM patient material. Photomicrograph 
of H&E-stained (original magnification 4×) GBM patient material showing pseudopalisading necrosis characterized by 
a garland-like arrangement of hypercellular tumor nuclei (arrows) lining up around irregular foci of tumor necrosis (A). 
Immunohistochemical staining for GLUT1, ZEB1 and YKL40 in consecutive sections detected overlapping expression 
patterns of these markers in pseudopalisading cells (100× original magnification, B). The areas indicated with boxes 
are enlarged; asterisk: necrotic region.
 Subsequently, we performed immunohistochemical staining on serial sections made 
from this material for GLUT1, a hypoxia marker, ZEB1 and the mesenchymal marker YKL40. 
Interestingly, we noticed an overlapping expression of these markers in the hypercellular 
zones/pseudopalisades surrounding the necrotic foci (Figure 6B). Taken together this 
provides further evidence for a link between hypoxia and ZEB1-mediated mesenchymal 
transition in GBM.
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Discussion
Hypoxic regions are frequently found in GBM and the presence of extensive hypoxic 
areas has been associated with worse prognosis in GBM patients, which has been linked 
to hypoxic cancer cells displaying a more malignant phenotype and being more resistant 
to chemotherapy and radiation [32-34]. The HIF transcription factors are instrumental for 
orchestrating adaptive responses to cope with oxygen shortage, and particularly HIF-1α 
is key in inducing expression of glycolytic enzymes and several angiogenic growth factors 
[12,17,35]. HIF-1α was found to be upregulated in many of the malignant tumors primarily by 
hypoxia-mediated protein stabilization [12].
 In GBM, HIF-1α seems to be primarily localized to the pseudopalisading cells around 
necrotic cores and to tumor cells at the invasive edge of the tumor that infiltrate the normal 
brain tissue [36]. Extensive necrosis and elevated levels of HIF-regulated genes are features 
that were more frequently found in mesenchymal GBM when compared to proneural GBM 
[4,6,37]. Despite the association between hypoxia and mesenchymal GBM, the potential 
molecular mediators that induce a mesenchymal shift under hypoxic condition remains a 
poorly studied area.
 In the present study we showed that hypoxia is a strong inducer of a mesenchymal 
shift in GBM that was associated with morphological changes, upregulation of known 
mesenchymal markers like fibronectin and COL5A1 and elevated invasive potential in vitro. 
We independently tested the role of the two HIF-α proteins – HIF-1α and HIF-2α, as we 
observed the up-regulation and nuclear translocation of both of these HIF proteins under 
hypoxic conditions. HIF-1α is the most well studied member of the HIF-α family due to its 
universal pattern of expression, unlike HIF-2α that shows a more restricted expression 
pattern. Notably, HIF-2α has been reported to play a crucial role in regulating stemness 
in GBM [38-40]. We found that hypoxia-induced HIF-1α, and not HIF-2α, is a key mediator 
for mesenchymal transition. The EMT transcription factor ZEB1 known to regulate EMT in 
epithelial cancers [41,42] appeared instrumental in this transition since siRNA-dependent 
silencing of ZEB1 prevented the hypoxia-induced mesenchymal shift and enhanced 
invasive capacity. Our finding of overlapping ZEB1, GLUT1 and YKL40 expression patterns 
surrounding necrotic areas in GBM patient material provides evidence for the occurrence of 
local hypoxia-induced ZEB1-mediated mesenchymal transition in these tumors. Interestingly, 
ZEB1 has been recently associated with invasive behavior, temozolomide resistance and 
stemness in GBM [43]. Moreover, we previously identified a critical role for ZEB1 in mediating 
a TGF-β-induced mesenchymal shift in GBM cells [28]. Furthermore, the TNF-α/NF-κB and 
WNT/β-catenin pathways were also reported to be able to mediate a mesenchymal shift in 
GBM [44,45]. Of note, hypoxia did not trigger a mesenchymal shift in U251 cells, whereas 
previously we found that these cells underwent such transdifferentiation upon TGF-β 
exposure [28]. Apparently, some GBM cells are refractory to one mesenchymal-inducing 
stimulus while being sensitive to others providing multiple ways for GBM cell to acquire the 
aggressive mesenchymal status. The mesenchymal phenotype in GBM, in addition to being 
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regulated by the transcription factors C/EBP-β, STAT3 and TAZ [6,46], is thus controlled by 
various external stimuli. How and whether these mechanisms are further interlinked remains 
to be investigated.
 In summary, as indicated in Figure 7, hypoxia induces a mesenchymal shift in GBM that 
is mediated by the HIF-1α–ZEB1 axis leading to an elevated invasive potential. Our results 
further indicate the crucial role of micro-environmental factors like hypoxia in defining GBM 
subtypes and thus the boundaries between these molecular subtypes appear less strict than 
initially believed. Hence, therapeutic targeting of HIF-1α or its downstream target ZEB1 might 
provide a possible strategy for improving the prognoses for GBM patients.
Figure 7. Model illustrating hypoxia-induced mesenchymal transition in GBM that is mediated by HIF-1α and ZEB1. 
Mesenchymal transition contributes to GBM subtype heterogeneity and the gain of an invasive phenotype.
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Supporting information
Supplemental Figures
Supplemental Figure 1. HIF-1α expression and migration capacity of U251 cells under hypoxia. Wound-healing assay 
(10× magnification) showing reduced migration potential of U251 cells when exposed to hypoxia, contrasting the 
elevated migration potential of hypoxia-exposed U87 cells (A, B). Immunofluorescence microscopic image (40× 
magnification) of U251 cells showing nuclear localization of HIF-1α under hypoxic condition (C). Immunofluorescence 
microscopic image (40× magnification) of U251 cells showing the absence of ZEB1 nuclear localization under hypoxic 
conditions (D).
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Supplemental Figure 2. Hypoxia stabilizes HIF-1α, HIF-2α and ZEB1 in U87 cells. The time course analysis shows 
relatively earlier induction of HIF-1α, HIF-2α, ZEB1 protein expression, and also levels of the mesenchymal marker 
fibronectin become elevated after endured hypoxia exposure (>48 hours). 
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Supplemental Figure 3. Dose-dependent inhibition by digoxin of hypoxia-induced mesenchymal shift. Different doses 
of digoxin were administrated under hypoxic conditions and the effect on cell morphology was evaluated; images 
captured at 10× magnification (A). Western blots showing different levels of inhibition of HIF-1α and fibronectin under 
hypoxia following digoxin administration at varying doses (B).
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